CD69 blockade restores the bone marrow niche and delays leukemogenesis in a mouse model of Nras G12D-driven chronic myelomonocytic leukemia.

IF 5.7 4区 医学 Q2 ONCOLOGY Cancer Biology & Therapy Pub Date : 2026-12-31 Epub Date: 2026-06-22 DOI:10.1080/15384047.2026.2692184
Yuchen Li, Xu Jiang, Yinfeng Gu, Xianfeng Zha, Jie Wu, Xiuli Wu, Chunli Qi, Shaohua Chen, Yangqiu Li, Zhenyi Jin, Chengxiang Xia, Ling Xu
{"title":"CD69 blockade restores the bone marrow niche and delays leukemogenesis in a mouse model of <i>Nras</i> <sup>G12D</sup>-driven chronic myelomonocytic leukemia.","authors":"Yuchen Li, Xu Jiang, Yinfeng Gu, Xianfeng Zha, Jie Wu, Xiuli Wu, Chunli Qi, Shaohua Chen, Yangqiu Li, Zhenyi Jin, Chengxiang Xia, Ling Xu","doi":"10.1080/15384047.2026.2692184","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>A subset of patients with chronic myelomonocytic leukemia (CMML) carries <i>NRAS</i> mutations, which are associated with shorter overall survival and an increased risk of transformation to acute myeloid leukemia. However, the effects of <i>NRAS</i> mutations on the bone marrow microenvironment (BME) remain unclear.</p><p><strong>Methods: </strong>We used a CMML mouse model driven by a single <i>Nras</i> <sup>G12D</sup> allele mutation to investigate alterations in the BME and the potential role of CD69 in immune suppression. <i>Nras</i> <sup>G12D</sup>-mutated CMML mice were treated with an anti-CD69 monoclonal antibody. Flow cytometry, hematoxylin-eosin staining, and RNA sequencing were performed to evaluate treatment-related changes.</p><p><strong>Results: </strong><i>Nras</i> <sup>G12D</sup>-mutated CMML mice showed increased infiltration of regulatory T (Treg) cells and CD69<sup>+</sup> T cells in the BME, whereas CD69 expression on peripheral blood T cells remained lower than that on bone marrow T cells. Anti-CD69 monoclonal antibody treatment was associated with reduced generation of granulocyte-macrophage progenitor cells, prolonged survival, and decreased Treg accumulation in the BME.</p><p><strong>Conclusion: </strong>Our findings suggest that CD69 may serve as a biomarker of BME immunological dysfunction in CMML.</p>","PeriodicalId":9536,"journal":{"name":"Cancer Biology & Therapy","volume":"27 1","pages":"2692184"},"PeriodicalIF":5.7000,"publicationDate":"2026-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13290085/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cancer Biology & Therapy","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/15384047.2026.2692184","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2026/6/22 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Background: A subset of patients with chronic myelomonocytic leukemia (CMML) carries NRAS mutations, which are associated with shorter overall survival and an increased risk of transformation to acute myeloid leukemia. However, the effects of NRAS mutations on the bone marrow microenvironment (BME) remain unclear.

Methods: We used a CMML mouse model driven by a single Nras G12D allele mutation to investigate alterations in the BME and the potential role of CD69 in immune suppression. Nras G12D-mutated CMML mice were treated with an anti-CD69 monoclonal antibody. Flow cytometry, hematoxylin-eosin staining, and RNA sequencing were performed to evaluate treatment-related changes.

Results: Nras G12D-mutated CMML mice showed increased infiltration of regulatory T (Treg) cells and CD69+ T cells in the BME, whereas CD69 expression on peripheral blood T cells remained lower than that on bone marrow T cells. Anti-CD69 monoclonal antibody treatment was associated with reduced generation of granulocyte-macrophage progenitor cells, prolonged survival, and decreased Treg accumulation in the BME.

Conclusion: Our findings suggest that CD69 may serve as a biomarker of BME immunological dysfunction in CMML.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
在Nras g12d驱动的慢性髓细胞白血病小鼠模型中,CD69阻断恢复骨髓生态位并延缓白血病的发生。
背景:一部分慢性髓细胞白血病(CMML)患者携带NRAS突变,这与较短的总生存期和转化为急性髓细胞白血病的风险增加有关。然而,NRAS突变对骨髓微环境(BME)的影响尚不清楚。方法:我们使用单个Nras G12D等位基因突变驱动的CMML小鼠模型来研究BME的改变和CD69在免疫抑制中的潜在作用。用抗cd69单克隆抗体处理Nras g12d突变的CMML小鼠。采用流式细胞术、苏木精-伊红染色和RNA测序来评估治疗相关的变化。结果:Nras g12d突变的CMML小鼠BME中调节性T (Treg)细胞和CD69+ T细胞的浸润增加,而外周血T细胞中CD69的表达仍然低于骨髓T细胞。抗cd69单克隆抗体治疗与粒细胞-巨噬细胞祖细胞的生成减少、生存时间延长和BME中Treg积累减少有关。结论:CD69可能是CMML患者BME免疫功能障碍的生物标志物。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Cancer Biology & Therapy
Cancer Biology & Therapy 医学-肿瘤学
CiteScore
7.00
自引率
0.00%
发文量
60
审稿时长
2.3 months
期刊介绍: Cancer, the second leading cause of death, is a heterogenous group of over 100 diseases. Cancer is characterized by disordered and deregulated cellular and stromal proliferation accompanied by reduced cell death with the ability to survive under stresses of nutrient and growth factor deprivation, hypoxia, and loss of cell-to-cell contacts. At the molecular level, cancer is a genetic disease that develops due to the accumulation of mutations over time in somatic cells. The phenotype includes genomic instability and chromosomal aneuploidy that allows for acceleration of genetic change. Malignant transformation and tumor progression of any cell requires immortalization, loss of checkpoint control, deregulation of growth, and survival. A tremendous amount has been learned about the numerous cellular and molecular genetic changes and the host-tumor interactions that accompany tumor development and progression. It is the goal of the field of Molecular Oncology to use this knowledge to understand cancer pathogenesis and drug action, as well as to develop more effective diagnostic and therapeutic strategies for cancer. This includes preventative strategies as well as approaches to treat metastases. With the availability of the human genome sequence and genomic and proteomic approaches, a wealth of tools and resources are generating even more information. The challenge will be to make biological sense out of the information, to develop appropriate models and hypotheses and to translate information for the clinicians and the benefit of their patients. Cancer Biology & Therapy aims to publish original research on the molecular basis of cancer, including articles with translational relevance to diagnosis or therapy. We will include timely reviews covering the broad scope of the journal. The journal will also publish op-ed pieces and meeting reports of interest. The goal is to foster communication and rapid exchange of information through timely publication of important results using traditional as well as electronic formats. The journal and the outstanding Editorial Board will strive to maintain the highest standards for excellence in all activities to generate a valuable resource.
期刊最新文献
Identification of coilin in bone marrow as a potential neuroblastoma tumor progression marker transcriptionally regulated by MYCN. Statement of Retraction: Didox (A Novel Ribonucleotide Reductase Inhibitor) Overcomes bc.l-2 Mediated Radiation Resistance in Prostate Cancer Cell Line PC-3. PI3Kγ inhibition drives M1 macrophage differentiation and synergizes with PD-L1 blockade to improve survival in poorly immunogenic head and neck squamous cell carcinoma. Interaction between ZMIZ2 and AR promotes prostate cancer proliferation in vitro and in vivo. Assessing progesterone receptor modulation in glioblastoma: from in vitro and animal model to a human pilot protocol.
wanfang
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1